Furthermore, dual-target adenosine-axis strategies—such as CD39/CD73 bispecific antibodies and multitarget metabolic inhibitors—aim to overcome compensatory enzymatic redundancy and more effectively suppress adenosine production within the tumor microenvironment (TME) (3, 7, 55). The gene discussed is NT5E; the disease is neoplasm.